Study of TJ011133 in Participants With Relapsed/Refractory Advanced Solid Tumors and Lymphoma
Public ClinicalTrials.gov record NCT03934814. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1 Study of TJ011133 Administered Alone or in Combination With Pembrolizumab or Rituximab in Subjects With Relapsed/Refractory Advanced Solid Tumors and Lymphoma
Study identification
- NCT ID
- NCT03934814
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- I-Mab Biopharma US Limited
- Industry
- Enrollment
- 98 participants
Conditions and interventions
Conditions
Interventions
- TJ011133 Drug
- Pembrolizumab Drug
- Rituximab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 15, 2019
- Primary completion
- Jan 9, 2023
- Completion
- Jan 9, 2023
- Last update posted
- Jun 30, 2024
2019 – 2023
United States locations
- U.S. sites
- 12
- U.S. states
- 11
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama - Birmingham | Birmingham | Alabama | 35233 | — |
| Mayo Clinic | Scottsdale | Arizona | 85259 | — |
| Yale School of Medicine | New Haven | Connecticut | 06510 | — |
| Mayo Clinic | Jacksonville | Florida | 32224 | — |
| Horizon Oncology | Lafayette | Indiana | 47905 | — |
| University of Michigan | Ann Arbor | Michigan | 48109 | — |
| Henry Ford Cancer Institute/Henry Ford Hospital | Detroit | Michigan | 48202 | — |
| Mayo Clinic | Rochester | Minnesota | 55905 | — |
| Rutgers Cancer Institute of New Jersey | New Brunswick | New Jersey | 08901 | — |
| NYU Langone Health | New York | New York | 10016 | — |
| Vanderbilt-Ingram Cancer Center | Nashville | Tennessee | 37203 | — |
| Seattle Cancer Care Alliance | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 9 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03934814, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 30, 2024 · Synced Jun 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03934814 live on ClinicalTrials.gov.